Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study

被引:12
|
作者
Choi, Soojeong [1 ]
Lee, Young Jae [2 ]
Jeong, Jae Ho [3 ]
Jung, Jinhong [4 ]
Lee, Jong Won [1 ]
Kim, Hee Jeong [1 ]
Ko, Beom Seok [1 ]
Son, Byung Ho [1 ]
Ahn, Sei Hyun [1 ]
Lee, Yura [1 ,5 ]
Chung, Il Yong [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Obstet & Gynecol, Kangnung, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med Informat, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
breast neoplasms; dilatation and curettage; gynecological examination; tamoxifen; endometrial neoplasms; SURGICAL ADJUVANT BREAST; ENDOCRINE THERAPY; LONG-TERM; WOMEN; PREVENTION; SOCIETY;
D O I
10.3389/fonc.2021.636378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors has not yet been fully assessed. This study aimed to investigate the risk of developing endometrial cancer and the frequencies of gynecological examinations in young breast cancer survivors taking TAM in South Korea. Methods A nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment Service claims data. Kaplan-Meier analyses and log-rank tests were used to assess the probability of endometrial cancer, benign endometrial conditions, and the probability of invasive endometrial procedure. To analyze the risk of endometrial cancer and benign endometrial conditions, we used a multivariable Cox proportional hazards regression model. Results Between 2010 and 2015, 60,545 newly diagnosed female breast cancer survivors were included. The total person-years were 256,099 and 140 (0.23%) patients developed endometrial cancer during the study period. In breast cancer survivors aged >= 60 years [hazard ratio (HR), 5.037; 95% confidence interval (CI), 2.185-11.613], 50-59 years (HR, 4.343; 95% CI, 2.122-8.891), and 40-49 years (HR, 2.121; 95% CI, 1.068-4.213), TAM was associated with an increased risk of endometrial cancer. In subjects aged below 40 years, TAM did not significantly increase the risk of endometrial cancer. However, among the TAM subgroups, breast cancer survivors aged below 40 years [1.61 per 1,000 person-years (PY); HR, 12.460; 95% CI, 2.698-57.522] and aged 40-49 years (2.22 per 1,000 PY; HR, 9.667; 95% CI, 4.966-18.819) with TAM-related endometrial diseases showed significantly increased risks of endometrial cancer. Among the TAM subgroup with benign endometrial conditions, the ratios of the frequency of invasive diagnostic procedures to the incidence of endometrial cancer were higher in subjects under 40 than subjects aged 60 or more. Conclusion Young breast cancer survivors with TAM-related benign endometrial diseases are at a higher risk of developing endometrial cancer. Gynecological surveillance should be tailored to the risk of endometrial cancer in young breast cancer survivors to improve the early detection of endometrial cancer and avoid unnecessary invasive procedures.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
    Ryu, Ki-Jin
    Kim, Min Sun
    Lee, Ji Yoon
    Nam, Seunghyun
    Jeong, Hye Gyeong
    Kim, Tak
    Park, Hyuntae
    JAMA NETWORK OPEN, 2022, 5 (11) : E2243951
  • [32] Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen
    Ignatov, Atanas
    Ortmann, Olaf
    CANCERS, 2020, 12 (07) : 1 - 10
  • [33] Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy
    Sasco, AJ
    Chaplain, G
    Amoros, E
    Saez, S
    EPIDEMIOLOGY, 1996, 7 (01) : 9 - 13
  • [34] Fracture history and risk of breast and endometrial cancer
    Newcomb, PA
    Trentham-Dietz, A
    Egan, KM
    Titus-Ernstoff, L
    Baron, JA
    Storer, BE
    Willett, WC
    Stampfer, MJ
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : 1071 - 1078
  • [35] Endometrial cancer associated with an increase of CA 15_3 and CA 125 in tamoxifen treated patients with breast cancer
    Mekic-Abazovic, Alma
    Beculic, Hakija
    Music, Miralem
    Fajkic, Almir
    Dervisevic, Senad
    MEDICINSKI GLASNIK, 2011, 8 (01) : 68 - 71
  • [36] Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens
    Cohen, I
    Figer, A
    Altaras, MM
    Tepper, R
    Shapira, J
    Cordoba, M
    Yigael, D
    Arbel, Y
    Beyth, Y
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1996, 15 (01) : 17 - 22
  • [38] Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer
    Timmerman, D
    Deprest, J
    Verbesselt, R
    Moerman, P
    De Brabanter, J
    Vergote, I
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S40 - S42
  • [39] Different coexisting gynecological and endometrial pathologies in postmenopausal breast cancer patients treated with tamoxifen
    Cohen, I
    Beyth, Y
    Bernheim, J
    Shapira, J
    Cordoba, M
    Aviram, R
    Figer, A
    Yigael, D
    Altaras, MM
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1998, 46 (02) : 123 - 129
  • [40] Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
    Baek, Soo Yeon
    Kwon, Ji Yeong
    Lee, Young Joo
    Gwark, Sung-chan
    Lee, Sae Byul
    Kim, Jisun
    Chung, Il Yong
    Ko, Beom Seok
    Kim, Hee Jeong
    Kim, Sung-Bae
    Ahn, Seung Do
    Gong, Gyungyub
    Son, Byung Ho
    Ahn, Sei-Hyun
    Lee, Jong Won
    JOURNAL OF BREAST CANCER, 2019, 22 (03) : 387 - 398